Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension

Nazzareno Galiè, Alan L. Hinderliter, Adam Torbicki, Thierry Fourme, Gerald Simonneau, Tomas Pulido, Nilda Espinola-Zavaleta, Guido Rocchi, Alessandra Manes, Robert Frantz, Marcin Kurzyna, Sherif F. Nagueh, Robyn Barst, Richard Channick, Karl Dujardin, Andrew Kronenberg, Isabelle Leconte, Maurizio Rainisio, Lewis Rubin

Research output: Contribution to journalArticle

291 Citations (Scopus)

Abstract

OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH). BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH. METHODS: Patients had primary pulmonary hypertension (84%) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment. RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardio graphic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.41/min/m2 (p = 0.007); LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = -0.12 (p = 0.047), RV end-systolic area = -2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = -0.64 (p = 0.007), Doppler RV index = -0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17% (p = 0.05). CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.

Original languageEnglish (US)
Pages (from-to)1380-1386
Number of pages7
JournalJournal of the American College of Cardiology
Volume41
Issue number8
DOIs
StatePublished - Apr 2003

Fingerprint

Pulmonary Hypertension
Placebos
Right Ventricular Function
Connective Tissue Diseases
Pericardial Effusion
Random Allocation
bosentan
Endothelin Receptor Antagonists
Left Ventricular Function
Walking
Dilatation
Therapeutics
Hemodynamics
Exercise

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. / Galiè, Nazzareno; Hinderliter, Alan L.; Torbicki, Adam; Fourme, Thierry; Simonneau, Gerald; Pulido, Tomas; Espinola-Zavaleta, Nilda; Rocchi, Guido; Manes, Alessandra; Frantz, Robert; Kurzyna, Marcin; Nagueh, Sherif F.; Barst, Robyn; Channick, Richard; Dujardin, Karl; Kronenberg, Andrew; Leconte, Isabelle; Rainisio, Maurizio; Rubin, Lewis.

In: Journal of the American College of Cardiology, Vol. 41, No. 8, 04.2003, p. 1380-1386.

Research output: Contribution to journalArticle

Galiè, N, Hinderliter, AL, Torbicki, A, Fourme, T, Simonneau, G, Pulido, T, Espinola-Zavaleta, N, Rocchi, G, Manes, A, Frantz, R, Kurzyna, M, Nagueh, SF, Barst, R, Channick, R, Dujardin, K, Kronenberg, A, Leconte, I, Rainisio, M & Rubin, L 2003, 'Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension', Journal of the American College of Cardiology, vol. 41, no. 8, pp. 1380-1386. https://doi.org/10.1016/S0735-1097(03)00121-9
Galiè, Nazzareno ; Hinderliter, Alan L. ; Torbicki, Adam ; Fourme, Thierry ; Simonneau, Gerald ; Pulido, Tomas ; Espinola-Zavaleta, Nilda ; Rocchi, Guido ; Manes, Alessandra ; Frantz, Robert ; Kurzyna, Marcin ; Nagueh, Sherif F. ; Barst, Robyn ; Channick, Richard ; Dujardin, Karl ; Kronenberg, Andrew ; Leconte, Isabelle ; Rainisio, Maurizio ; Rubin, Lewis. / Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. In: Journal of the American College of Cardiology. 2003 ; Vol. 41, No. 8. pp. 1380-1386.
@article{6ef44ebf285649fab631097007250608,
title = "Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension",
abstract = "OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH). BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH. METHODS: Patients had primary pulmonary hypertension (84{\%}) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment. RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardio graphic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.41/min/m2 (p = 0.007); LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = -0.12 (p = 0.047), RV end-systolic area = -2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = -0.64 (p = 0.007), Doppler RV index = -0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17{\%} (p = 0.05). CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.",
author = "Nazzareno Gali{\`e} and Hinderliter, {Alan L.} and Adam Torbicki and Thierry Fourme and Gerald Simonneau and Tomas Pulido and Nilda Espinola-Zavaleta and Guido Rocchi and Alessandra Manes and Robert Frantz and Marcin Kurzyna and Nagueh, {Sherif F.} and Robyn Barst and Richard Channick and Karl Dujardin and Andrew Kronenberg and Isabelle Leconte and Maurizio Rainisio and Lewis Rubin",
year = "2003",
month = "4",
doi = "10.1016/S0735-1097(03)00121-9",
language = "English (US)",
volume = "41",
pages = "1380--1386",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension

AU - Galiè, Nazzareno

AU - Hinderliter, Alan L.

AU - Torbicki, Adam

AU - Fourme, Thierry

AU - Simonneau, Gerald

AU - Pulido, Tomas

AU - Espinola-Zavaleta, Nilda

AU - Rocchi, Guido

AU - Manes, Alessandra

AU - Frantz, Robert

AU - Kurzyna, Marcin

AU - Nagueh, Sherif F.

AU - Barst, Robyn

AU - Channick, Richard

AU - Dujardin, Karl

AU - Kronenberg, Andrew

AU - Leconte, Isabelle

AU - Rainisio, Maurizio

AU - Rubin, Lewis

PY - 2003/4

Y1 - 2003/4

N2 - OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH). BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH. METHODS: Patients had primary pulmonary hypertension (84%) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment. RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardio graphic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.41/min/m2 (p = 0.007); LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = -0.12 (p = 0.047), RV end-systolic area = -2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = -0.64 (p = 0.007), Doppler RV index = -0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17% (p = 0.05). CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.

AB - OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH). BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH. METHODS: Patients had primary pulmonary hypertension (84%) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment. RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardio graphic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.41/min/m2 (p = 0.007); LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = -0.12 (p = 0.047), RV end-systolic area = -2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = -0.64 (p = 0.007), Doppler RV index = -0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17% (p = 0.05). CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.

UR - http://www.scopus.com/inward/record.url?scp=0344837813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344837813&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(03)00121-9

DO - 10.1016/S0735-1097(03)00121-9

M3 - Article

C2 - 12706935

AN - SCOPUS:0344837813

VL - 41

SP - 1380

EP - 1386

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 8

ER -